Cytokinetics, Inc. — Q2 2015 Form 10-Q
Business context and reporting period
Clinical-stage biopharmaceutical company developing small-molecule therapies that modulate muscle function. This filing covers the quarter and six months ended June 30, 2015; financial statements are unaudited. Its principal clinical programs are tirasemtiv for ALS, CK-2127107 for SMA and other muscle-weakness conditions, and partner-led omecamtiv mecarbil for heart failure. The company has no commercial product sales.
Financial results and liquidity
| Metric | Q2 2015 | Q2 2014 | Six months 2015 | Six months 2014 |
|---|---|---|---|---|
| Revenue | $6.5 million | $7.8 million | $11.0 million | $15.8 million |
| Research and development expense | $12.6 million | $11.7 million | $21.6 million | $24.2 million |
| General and administrative expense | $4.5 million | $4.5 million | $8.9 million | $8.7 million |
| Operating loss | $10.6 million | $8.4 million | $19.5 million | $17.2 million |
| Net loss | $10.6 million | $8.4 million | $19.4 million | $17.1 million |
| Basic and diluted loss per share | $0.27 | $0.23 | $0.50 | $0.49 |
- Q2 revenue declined about 16% year over year; six-month revenue declined about 31%. Revenue is collaboration, license and reimbursement income, not product sales. The six-month decline largely reflects prior-period Astellas reimbursements and milestone revenue.
- Q2 operating loss widened about 26% year over year, while six-month operating loss widened about 14%. Q2 R&D expense rose about 8%, mainly from tirasemtiv/VITALITY-ALS preparation; six-month R&D expense fell about 11%, mainly because BENEFIT-ALS costs ended.
- At June 30, cash and cash equivalents were $24.8 million; short- and long-term investments totaled $83.4 million. Combined cash and investments were $108.2 million, versus $83.2 million at year-end 2014. Current assets were $107.9 million and current liabilities $29.1 million. No debt balance is reported in the presented balance sheet.
- Six-month operating cash flow was positive $25.2 million, versus negative $27.2 million in 2014. This was principally attributable to collection of the $45.0 million Astellas receivable; it should not be read as evidence of cash-generative operations. Investing cash flow was negative $20.7 million and financing cash flow was positive $0.1 million.
- Accumulated deficit was $516.7 million. The company reported no income-tax provision and no material change in market-risk exposure. It stated existing cash, cash equivalents and investments should fund requirements for at least 12 months, while anticipating future operating losses and cash outflows.
Material changes, outlook and commentary
- Astellas paid $30 million upfront and a $15 million milestone in January 2015 under its expanded collaboration; the company also received $10 million for shares sold to Astellas in December 2014. Astellas collaboration revenue is recognized over the research term, and $29.3 million remained deferred at June 30.
- Management forecast 2015 revenue of $31–34 million, R&D expense of $59–62 million, and G&A expense of $21–23 million. These are company estimates, not guaranteed results.
- In July 2015, after quarter-end, Cytokinetics began the Phase 3 VITALITY-ALS trial of tirasemtiv. The trial assesses slow vital capacity (SVC) and other respiratory measures. The company noted regulators may not consider SVC alone sufficient to establish clinical benefit; further trials could be required. BENEFIT-ALS did not meet its primary ALS functional-rating endpoint, although management described SVC effects as robust and potentially meaningful.
- The company anticipated starting a Phase 2 CK-2127107 SMA trial in the second half of 2015, with planning targeting the fourth quarter. It expected COSMIC-HF results for partner Amgen’s oral omecamtiv mecarbil study in Q4 2015.
- Potential Astellas and Amgen development, commercial and sales milestones are substantial but contingent on future research, clinical, regulatory or sales outcomes. The timing and likelihood of receipt are uncertain; future royalties also depend on successful commercialization.
- Key risks include clinical and regulatory failure or delay, uncertainty about the acceptability of tirasemtiv endpoints, reliance on partner decisions and funding, need for additional capital, lack of product revenue, manufacturing and CRO execution, competition, intellectual-property protection and possible dilution from equity issuance or outstanding warrants and options.
- Legal proceedings concern Pharm-Olam’s data-management work on BENEFIT-ALS. Cytokinetics seeks monetary damages, alleging contract and other failures that caused trial delays and added costs; Pharm-Olam separately sought declaratory relief, and Datatrak was permitted to intervene after quarter-end. No recovery was recognized in the financial statements.
Important facts for investors to verify
- Whether cash and investments, excluding the one-time Astellas receipt, support the stated 12-month runway and the planned clinical spending.
- Progress, enrollment, safety and endpoint results for VITALITY-ALS, and regulatory feedback on whether SVC and secondary measures can support an approval application.
- Timing and outcomes of the CK-2127107 SMA trial and COSMIC-HF results, as well as Amgen’s and Astellas’ continued commitment to their programs.
- Achievement and accounting recognition of collaboration reimbursements, milestones and deferred revenue underlying the 2015 revenue outlook.
- Outcome and potential recovery, if any, in the Pharm-Olam/Datatrak litigation; the filing does not provide a clear value for potential damages.
- Potential dilution: 5.6 million warrants were outstanding at June 30, 2015, exercisable at $5.28 per share and expiring June 25, 2017. Common shares outstanding were 38.75 million as of July 30, 2015.